

CLAIMS

1. An anticancer agent comprising BL-angiostatin as an active ingredient thereof.
- 5 2. The anticancer agent according to claim 1 wherein the BL-angiostatin is derived from a mammal.
3. The anticancer agent according to claim 1 or 2 wherein the BL-angiostatin is selected from a group consisting of Glu<sup>1</sup>-Ser<sup>441</sup>, Glu<sup>1</sup>-Val<sup>449</sup>, Phe<sup>75</sup>-Ser<sup>441</sup> and Phe<sup>75</sup>-Val<sup>449</sup> fragments  
10 of human plasminogen.
4. A method for producing the BL-angiostatin according to claim 1 comprising the steps of:
  - equilibrating an affinity trap reactor, in which bacillolysin MA and lysine are immobilized on agarose gel,  
15 with a buffer;
  - adding serum treated with citric acid;
  - washing with a buffer containing sodium chloride; and
  - eluting with 6-aminohexanoic acid; wherein,  
the buffer does not contain isopropyl alcohol.